Some evening reading:
Patsnap is a “general radar” that Big Pharmas can use when scouting potential drug candidate / target company opportunities. A closer look is left for the potential partner/buyer to do themselves.
Here is its latest update on BEX/Faron, which neatly wraps up existing information into one package.
It gives a rating of “Conditional Go”, so no need to rush to the market square to celebrate—at least not yet.
“CONDITIONAL GO
Bexmarilimab is a Monoclonal antibody associated with STAB1 and a global highest development stage of Phase 2. The lead disclosed indication is High Risk Myelodysplastic Syndrome. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights. ”
“Matched asset deals: 0” = Has not been sold